Vaccination in Pregnancy against Pertussis: A Consensus Statement on Behalf of the Global Pertussis Initiative

Abu-Raya, Bahaa; Forsyth, Kevin; Halperin, Scott A.; Maertens, Kirsten; Jones, Christine E; Heininger, Ulrich; Hozbor, Daniela Flavia; König, Carl Heinz Wirsing von; Chitkara, A. J.; Muloiwa, Rudzani; Tan, Tina Q.

doi:10.3390/vaccines10121990

Cited by 16 publications

(21 citation statements)

References 125 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Many countries have recommended Tetanus-diphtheriaacellular pertussis for women during pregnancy since 2011, [14][15][16][17] which can prevent pertussis disease in infants and is safe for both mother and fetus. [18,19] However, routine pertussis vaccination during pregnancy is not yet recommend by the Chinese Center for Disease Control and Prevention at present. In this case report, the mother did not receive pertussis vaccine during pregnancy.…”

Section: Discussionmentioning

confidence: 99%

Metagenomics next-generation sequencing assists in the diagnosis of infant pertussis encephalopathy: A case report

Zhang

Wang

Xia³

et al. 2023

Medicine

View full text Add to dashboard Cite

Rationale: Pertussis is an acute respiratory infection that often occurs in the pediatric population, especially in infants under 3 months old. Bordetella pertussis is the causative agent of pertussis, which can lead to pneumonia, encephalopathy, and pulmonary hypertension, causing death in severe cases. Therefore, an accurate and comprehensive diagnosis of the pathogen is essential for effective treatment. Patient concerns: We report a case of 2-month-old male infant admitted to the pediatric intensive care unit of West China Second University due to hoarse cough for 7 days, accompanied by a crowing-like echo, fever and listlessness, occasional nonprojectile vomiting with anorexia, shortness of breath, accelerated heart rate, cyanosis of the lips, and convulsions. B pertussis was identified by metagenomic next-generation sequencing in blood and cerebrospinal fluid and polymerase chain reaction assay using blood. Diagnoses: The infant was diagnosed with pertussis. Interventions: Intravenous infusion of erythromycin (50 mg/kg/d) for anti-infection and dexamethasone for alleviating intracranial inflammatory reaction were given. Outcomes: The patient was eventually recovered and discharged. Lessons: This case report emphasized the importance of metagenomic next-generation sequencing using cerebrospinal fluid and blood for early diagnosis of pertussis-associated encephalopathy.

show abstract

Section: Discussionmentioning

confidence: 99%

Metagenomics next-generation sequencing assists in the diagnosis of infant pertussis encephalopathy: A case report

Zhang

Wang

Xia³

et al. 2023

Medicine

View full text Add to dashboard Cite

show abstract

“…The added benefit of breastfeeding in infants of vaccinated people to clinical protection is unclear. Source: Table adapted, with permission, from Abu-Raya et al 13 The GPI group concluded that there are several potential areas that require further exploration to address Tdap vaccination rates in pregnancy (Table 4). Further data on the epidemiology of pertussis infection in specific regions and countries worldwide Abbreviation: Tdap, tetanus diphtheria and pertussis vaccine.…”

Section: B Pertussis Antibodies In Breast Milkmentioning

confidence: 99%

“…We focus on obstetric and gynecologic health care providers (Ob/Gyn) and the challenges faced, in addition to potential strategies for implementing worldwide pertussis vaccination in pregnancy. Day 1 discussions, recommendations, and outcomes are available 13 About the GPIIn 2001, the GPI was initiated to: (1) increase pertussis awareness in low‐, middle‐, and high‐income countries; and (2) develop evidence‐based vaccination recommendations/strategies to decrease the disease burden in persons of all ages.…”

Section: Introductionmentioning

confidence: 99%

The current state of pertussis vaccination in pregnancy around the world, with recommendations for improved care: Consensus statements from the Global Pertussis Initiative

Olson‐Chen,

Swamy,

Gonik

et al. 2024

Intl J Gynecology & Obste

Self Cite

View full text Add to dashboard Cite

Bordetella pertussis, which causes a respiratory disease known as pertussis ("whooping cough") remains an important global challenge, with the incidence in pertussis cases increasing in recent years. Newborns and infants are at increased risk for severe morbidity and mortality from this bacterium. Vaccination in pregnancy has become an important strategy to both passively transfer immunity as well as prevent infection in pregnant persons, who are a major source of newborn infection, thus attempting to decrease the impact of this serious disease. It is considered safe for the pregnant person, the developing fetus, and the infant, and during the first 3 months of life it has been shown to be highly effective in preventing pertussis. There are a variety of strategies, recommendations, and adherence rates associated with pertussis vaccination in pregnancy around the world. We summarize the 2021 Global Pertussis Initiative Annual Meeting that reviewed the current global status of pertussis vaccination in pregnancy and remaining medical and scientific questions, with a focus on vaccination challenges and strategies for obstetric and gynecologic healthcare providers.

show abstract

“…The resurgence of the disease has prompted a short to medium-term response, leading to the incorporation of additional vaccine boosters in the adolescent and adult population, particularly in pregnant women (20,21). The data collected so far indicate that pregnant women vaccination strategy is proving successful (22,23). However, challenges persist in vaccination strategies that require resolution.…”

Section: Introductionmentioning

confidence: 99%

Use of Mucosally Administered Outer Membrane Vesicles Derived fromBordetella pertussisto Diminish Nasal Bacterial Colonization

Rudi,

Gaillard,

Bottero

et al. 2024

Preprint

View full text Add to dashboard Cite

Background: We previously identified Bordetella pertussis-derived outer membrane vesicles (OMVs) as a promising immunogen for improving pertussis vaccines. In this study, we evaluated the efficacy of our vaccine prototype in immunization strategies aimed at reducing disease transmission by targeting colonization in the upper airways while maintaining protection against severe disease by reducing colonization in the lower respiratory tract. Methods: We assessed different mucosal administration strategies in a murine model, including homologous 2-dose schedules and heterologous prime-boost strategies combining intramuscular (IM) systemic immunization with mucosal routes (intranasal (IN) or sublingual (SL)). We utilized mucosal c-di-AMP and/or systemic alum adjuvants to formulate the OMV vaccine prototype. A homologous IM immunization schedule and commercial vaccines were used for comparison. Results: All tested heterologous schemes induced higher levels of specific IgG with significant avidity, as well as high levels of IgG1 and IgG2 compared, to corresponding homologous 2-dose schemes via mucosal routes (OMVIN-IN or OMVSL-SL). High IgA levels were observed post-B. pertussis challenge following OMVIN-IN treatments and heterologous treatments where the second dose was administered via a mucosal route. Furthermore, schemes involving the intranasal route, whether in a homologous or heterologous scheme, induced the highest levels of IL-17 and IFN-γ. Accordingly, these schemes showed superior efficacy against nasal colonization than the commercial vaccines. Specifically, homologous intranasal immunization exhibited the highest protective capacity against nasal colonization while maintaining an excellent level of protection in the lower respiratory tract. To enhance the protective capacity against nasal colonization further, we conducted a comparative analysis of formulations containing different adjuvants (c-di-AMP, alum, or a combination of both) administered via homologous intranasal routes. These assays revealed that the use of alum, either alone or in combination with c-di-AMP, did not enhance the immune protective capacity. Conclusions: All the experiments presented here highlight that the use of OMVs, regardless of the scheme utilized, with the exception of OMVSL-SL, outperformed acellular pertussis (aP) vaccines, achieving a greater reduction in bacterial colonization in the upper respiratory tract (p<0.001).

show abstract

Vaccination in Pregnancy against Pertussis: A Consensus Statement on Behalf of the Global Pertussis Initiative

Cited by 16 publications

References 125 publications

Metagenomics next-generation sequencing assists in the diagnosis of infant pertussis encephalopathy: A case report

Metagenomics next-generation sequencing assists in the diagnosis of infant pertussis encephalopathy: A case report

The current state of pertussis vaccination in pregnancy around the world, with recommendations for improved care: Consensus statements from the Global Pertussis Initiative

Use of Mucosally Administered Outer Membrane Vesicles Derived fromBordetella pertussisto Diminish Nasal Bacterial Colonization

Contact Info

Product

Resources

About